Autosomal dominant polycystic kidney disease
E Cornec-Le Gall, A Alam, RD Perrone - The Lancet, 2019 - thelancet.com
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary
kidney disease and one of the most common causes of end-stage kidney disease. Multiple …
kidney disease and one of the most common causes of end-stage kidney disease. Multiple …
The regulation of PKA signaling in obesity and in the maintenance of metabolic health
E London, CA Stratakis - Pharmacology & therapeutics, 2022 - Elsevier
The cAMP-dependent protein kinase (PKA) system represents a primary cell-signaling
pathway throughout systems and across species. PKA facilitates the actions of hormones …
pathway throughout systems and across species. PKA facilitates the actions of hormones …
Organoid-on-a-chip model of human ARPKD reveals mechanosensing pathomechanisms for drug discovery
K Hiratsuka, T Miyoshi, KT Kroll, NR Gupta… - Science …, 2022 - science.org
Organoids serve as a novel tool for disease modeling in three-dimensional multicellular
contexts. Static organoids, however, lack the requisite biophysical microenvironment such …
contexts. Static organoids, however, lack the requisite biophysical microenvironment such …
[PDF][PDF] Generation of human PSC-derived kidney organoids with patterned nephron segments and a de novo vascular network
Human pluripotent stem cell-derived kidney organoids recapitulate developmental
processes and tissue architecture, but intrinsic limitations, such as lack of vasculature and …
processes and tissue architecture, but intrinsic limitations, such as lack of vasculature and …
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney …
RU Müller, AL Messchendorp, H Birn… - Nephrology Dialysis …, 2022 - academic.oup.com
Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark
TEMPO 3: 4 trial—marked a transformation in the management of autosomal dominant …
TEMPO 3: 4 trial—marked a transformation in the management of autosomal dominant …
[HTML][HTML] Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease
PC Harris, VE Torres - The Journal of clinical investigation, 2014 - Am Soc Clin Investig
Recent advances in defining the genetic mechanisms of disease causation and modification
in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some …
in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some …
High fat diet-induced obesity leads to depressive and anxiety-like behaviors in mice via AMPK/mTOR-mediated autophagy
Y Li, Y Cheng, Y Zhou, H Du, C Zhang, Z Zhao… - Experimental …, 2022 - Elsevier
Depression is one of the most common mental illnesses in modern society. In recent years,
several studies show that there are disturbances in lipid metabolism in depressed patients …
several studies show that there are disturbances in lipid metabolism in depressed patients …
Intracellular cAMP sensor EPAC: physiology, pathophysiology, and therapeutics development
WG Robichaux III, X Cheng - Physiological reviews, 2018 - journals.physiology.org
This review focuses on one family of the known cAMP receptors, the exchange proteins
directly activated by cAMP (EPACs), also known as the cAMP-regulated guanine nucleotide …
directly activated by cAMP (EPACs), also known as the cAMP-regulated guanine nucleotide …
Autosomal dominant polycystic kidney disease: the changing face of clinical management
ACM Ong, O Devuyst, B Knebelmann, G Walz - The Lancet, 2015 - thelancet.com
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …
[HTML][HTML] Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy
H Yang, L Yang - Journal of molecular endocrinology, 2016 - jme.bioscientifica.com
In mammals, cyclic adenosine monophosphate (cAMP) is an intracellular second
messenger that is usually elicited by binding of hormones and neurotransmitters to G protein …
messenger that is usually elicited by binding of hormones and neurotransmitters to G protein …